BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 10091800)

  • 1. Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM; McCaffrey JA; Mazumdar M; Scher H; Vlamis V; Higgins G; Herr H; Bajorin DF
    Cancer; 1999 Mar; 85(5):1145-50. PubMed ID: 10091800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N
    Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma.
    Dodd PM; McCaffrey JA; Herr H; Mazumdar M; Bacik J; Higgins G; Boyle MG; Scher HI; Bajorin DF
    J Clin Oncol; 1999 Aug; 17(8):2546-52. PubMed ID: 10561321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
    Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
    Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Saxman SB; Propert KJ; Einhorn LH; Crawford ED; Tannock I; Raghavan D; Loehrer PJ; Trump D
    J Clin Oncol; 1997 Jul; 15(7):2564-9. PubMed ID: 9215826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of urothelial tract tumors.
    Yagoda A
    Cancer; 1987 Aug; 60(3 Suppl):574-85. PubMed ID: 3297286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R; Manola J; Roth BJ; See WA; Kuross S; Edelman MJ; Hudes GR; Wilding G
    Cancer; 2004 Apr; 100(8):1639-45. PubMed ID: 15073851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
    Kuroda M; Kotake T; Akaza H; Hinotsu S; Kakizoe T
    Jpn J Clin Oncol; 1998 Aug; 28(8):497-501. PubMed ID: 9769784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
    J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N; Weiselberg LR
    J Urol; 1988 Mar; 139(3):461-9. PubMed ID: 3343727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
    J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study.
    Pizzocaro G; Milani A; Piva L; Faustini M; Spino E
    Eur Urol; 1991; 20(2):89-92. PubMed ID: 1752280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y; Shirahase T; Shichiri Y; Habuchi T; Matsuda T; Nishimura K; Hida S; Okada Y; Yoshida O
    Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for advanced TCC of urothelium.
    Huang CH; Hsieh HH; Wang JM; Hsu K; Yang WC; Yu TJ
    J Formos Med Assoc; 1992 Jul; 91(7):699-703. PubMed ID: 1360298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers.
    Ogawa T; Gotoh A; Takenaka A; Hara I; Gohji K; Arakawa S; Matsumoto O; Kamidono S
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S66-71. PubMed ID: 1394822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H
    Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer.
    Ueki O; Hisazumi H; Uchibayashi T; Naito K; Tajiri S; Takemae K; Kawaguchi K; Kameda K; Nishino A; Nango C
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S72-6. PubMed ID: 1394823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination chemotherapy of advanced urothelial cancer with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC)].
    Nakagawa S; Nakao M; Toyoda K; Nukui M; Takada H; Ebisui K; Watanabe H; Kobayashi T; Maegawa M
    Nihon Hinyokika Gakkai Zasshi; 1988 Sep; 79(9):1510-5. PubMed ID: 3244217
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.